ArticleDiabetes care2026
Plasma Metabolite Associations for Risk and Laboratory Measures of Type 2 Diabetes in a Large-Scale Finnish Prospective Cohort.
Article in Diabetes care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
objectiveWe aimed to identify plasma metabolites significantly associated with existing type 2 diabetes (T2D), further characterize their associations with T2D-related laboratory measures and lifestyle-related risk factors, and evaluate their potential mediating and predictive roles for incident T2D. RESEARCH DESIGN AND
methodsWe performed metabolomic profiling in 10,163 Finnish men in the Metabolic Syndrome in Men (METSIM) study at baseline. Of these participants, 1,412 had prevalent T2D and 1,234 developed incident T2D during an average follow-up period of 13.6 years. We tested for associations of 979 named metabolites with prevalent T2D. For significant metabolites, we further evaluated their associations with 24 T2D-related laboratory measures of five groups and five T2D lifestyle-related risk factors. We performed an exploratory mediation analysis to examine the mediation effects of metabolites on incident T2D for the five risk factors. We evaluated metabolite associations with incident T2D and built exploratory metabolite predictive models for incident T2D.
resultsWe identified 193 plasma metabolites significantly associated with prevalent T2D at baseline, including 71 previously unreported. Of these 193 metabolites, 88 were associated with incident T2D. In participants with prevalent T2D, the 193 metabolites showed associations with zero to 24 (mean 10.2) T2D-related laboratory measures. Eighty-one metabolites partially mediated the associations of the five risk factors with T2D onset under standard mediation assumptions. The significant metabolites showed improved predictive ability for future T2D.
conclusionsThis study identifies T2D plasma metabolic biomarkers for further investigation in women and other populations. The findings enhance our understanding of T2D biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.